BioPharma Credit (BPCR) Competitors GBX 0.88 +0.01 (+1.39%) As of 11:10 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendInsider TradesBuy This Stock BPCR vs. PCT, ATST, PHLL, 3IN, ABDN, BUR, JGGI, RCP, EMG, and BPTShould you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include Polar Capital Technology Trust (PCT), Alliance Trust (ATST), Petershill Partners (PHLL), 3i Infrastructure (3IN), abrdn (ABDN), Burford Capital (BUR), JPMorgan Global Growth & Income (JGGI), RIT Capital Partners (RCP), Man Group (EMG), and Bridgepoint Group (BPT). These companies are all part of the "asset management" industry. BioPharma Credit vs. Polar Capital Technology Trust Alliance Trust Petershill Partners 3i Infrastructure abrdn Burford Capital JPMorgan Global Growth & Income RIT Capital Partners Man Group Bridgepoint Group BioPharma Credit (LON:BPCR) and Polar Capital Technology Trust (LON:PCT) are both financial services companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Do insiders and institutionals believe in BPCR or PCT? 41.5% of BioPharma Credit shares are owned by institutional investors. Comparatively, 43.2% of Polar Capital Technology Trust shares are owned by institutional investors. 6.2% of BioPharma Credit shares are owned by company insiders. Comparatively, 1.2% of Polar Capital Technology Trust shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer BPCR or PCT? BioPharma Credit received 1 more outperform votes than Polar Capital Technology Trust when rated by MarketBeat users. Likewise, 64.62% of users gave BioPharma Credit an outperform vote while only 64.34% of users gave Polar Capital Technology Trust an outperform vote. CompanyUnderperformOutperformBioPharma CreditOutperform Votes8464.62% Underperform Votes4635.38% Polar Capital Technology TrustOutperform Votes8364.34% Underperform Votes4635.66% Which has more risk & volatility, BPCR or PCT? BioPharma Credit has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Polar Capital Technology Trust has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Is BPCR or PCT more profitable? Polar Capital Technology Trust has a net margin of 96.56% compared to BioPharma Credit's net margin of 80.20%. Polar Capital Technology Trust's return on equity of 30.54% beat BioPharma Credit's return on equity.Company Net Margins Return on Equity Return on Assets BioPharma Credit80.20% 8.51% 4.98% Polar Capital Technology Trust 96.56%30.54%20.70% Does the media prefer BPCR or PCT? In the previous week, Polar Capital Technology Trust had 1 more articles in the media than BioPharma Credit. MarketBeat recorded 1 mentions for Polar Capital Technology Trust and 0 mentions for BioPharma Credit. Polar Capital Technology Trust's average media sentiment score of 1.66 beat BioPharma Credit's score of 0.00 indicating that Polar Capital Technology Trust is being referred to more favorably in the news media. Company Overall Sentiment BioPharma Credit Neutral Polar Capital Technology Trust Very Positive Which has stronger valuation & earnings, BPCR or PCT? BioPharma Credit has higher revenue and earnings than Polar Capital Technology Trust. Polar Capital Technology Trust is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioPharma Credit£12.99B0.08£10.42B£0.099.94Polar Capital Technology Trust£1.24B3.07£1.20B£101.863.18 SummaryPolar Capital Technology Trust beats BioPharma Credit on 9 of the 15 factors compared between the two stocks. Get BioPharma Credit News Delivered to You Automatically Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPCR vs. The Competition Export to ExcelMetricBioPharma CreditAsset Management IndustryFinancial SectorLON ExchangeMarket Cap£1.04B£1.19B£5.33B£2.66BDividend Yield13.43%4.41%4.18%5.05%P/E Ratio9.9421.7612.76134.20Price / Sales0.082,413.211,774.19215,719.11Price / Cash1.1960.4649.7128.02Price / Book0.011.151.343.79Net Income£10.42B£263.32M£1.22B£5.88B7 Day Performance0.46%0.17%0.50%0.55%1 Month Performance1.63%18.10%11.21%22.01%1 Year Performance2.58%2.29%13.09%118.75% BioPharma Credit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPCRBioPharma CreditN/AGBX 0.88+1.4%N/A+0.5%£1.04B£12.99B9.96N/APCTPolar Capital Technology TrustN/AGBX 329.50+0.3%N/A-89.2%£3.88B£1.24B3.23120News CoveragePositive NewsATSTAlliance TrustN/AN/AN/AN/A£3.58B£652.76M600.003PHLLPetershill Partners2.4716 of 5 starsGBX 223+1.6%GBX 240+7.6%+5.9%£3.03B£706.00M9.05N/ANews CoverageGap Down3IN3i InfrastructureN/AGBX 327-1.1%N/A-5.1%£3.02B£374M860.53N/AABDNabrdn0.9497 of 5 starsGBX 165+1.0%GBX 163.50-0.9%+10.4%£2.95B£1.49B9.384,719News CoverageBURBurford Capital2.3294 of 5 starsGBX 1,062-1.7%GBX 1,600+50.7%-8.7%£2.92B£299.55M19.00140News CoverageHigh Trading VolumeJGGIJPMorgan Global Growth & IncomeN/AGBX 551-0.5%N/A-1.4%£2.84B£660.56M4.54N/ANews CoveragePositive NewsRCPRIT Capital PartnersN/AGBX 1,884-0.7%N/A-0.3%£2.72B£103.46M16.2962Positive NewsEMGMan Group2.9539 of 5 starsGBX 173.50-2.2%GBX 278+60.2%-32.1%£2.50B£1.69B8.181,790BPTBridgepoint Group2.6534 of 5 starsGBX 295+0.3%GBX 359.33+21.8%+18.1%£2.44B£272.35M53.59391Gap Up Related Companies and Tools Related Companies Polar Capital Technology Trust Alternatives Alliance Trust Alternatives Petershill Partners Alternatives 3i Infrastructure Alternatives abrdn Alternatives Burford Capital Alternatives JPMorgan Global Growth & Income Alternatives RIT Capital Partners Alternatives Man Group Alternatives Bridgepoint Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BPCR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPharma Credit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BPCR Stock Free BPCR Stock Alerts